Efficacy of vinblastine in central nervous system Langerhans cell histiocytosis: a nationwide retrospective study
Open Access
- 12 December 2011
- journal article
- Published by Springer Science and Business Media LLC in Orphanet Journal of Rare Diseases
- Vol. 6 (1), 83
- https://doi.org/10.1186/1750-1172-6-83
Abstract
Vinblastine (VBL) is the standard treatment for systemic Langerhans cell histiocytosis (LCH), but little is known about its efficacy in central nervous system (CNS) mass lesions. A retrospective chart review was conducted. Twenty patients from the French LCH Study Group register met the inclusion criteria. In brief, they had CNS mass lesions, had been treated with VBL, and were evaluable for radiologic response. The median age at diagnosis of LCH was 11.5 years (range: 1-50). Intravenous VBL 6 mg/m2 was given in a 6-week induction treatment, followed by a maintenance treatment. The median total duration was 12 months (range: 3-30). Eleven patients received steroids concomitantly. Fifteen patients achieved an objective response; five had a complete response (CR: 25%), ten had a partial response (PR: 50%), four had stable disease (SD: 20%) and one patient progressed (PD: 5%). Of interest, four out of the six patients who received VBL without concomitant steroids achieved an objective response. With a median follow-up of 6.8 years, the 5-year event-free and overall survival was 61% and 84%, respectively. VBL was well-tolerated and there were no patient withdrawals due to adverse events. VBL, with or without steroids, could potentially be a useful therapeutic option in LCH with CNS mass lesions, especially for those with inoperable lesions or multiple lesions. Prospective clinical trials are warranted for the evaluation of VBL in this indication.Keywords
This publication has 31 references indexed in Scilit:
- 2′‐chlorodeoxyadenosine (2‐CdA) as salvage therapy for Langerhans cell histiocytosis (LCH). results of the LCH‐S‐98 protocol of the histiocyte societyPediatric Blood & Cancer, 2009
- Neurodegenerative central nervous system disease as late sequelae of Langerhans cell histiocytosis. Report from the Japan LCH Study GroupHaematologica, 2008
- Descriptive epidemiology of childhood Langerhans cell histiocytosis in France, 2000–2004Pediatric Blood & Cancer, 2008
- Analysis of outcome for patients with mass lesions of the central nervous system due to Langerhans cell histiocytosis treated with 2‐chlorodeoxyadenosinePediatric Blood & Cancer, 2007
- Expansion of Regulatory T Cells in Patients with Langerhans Cell HistiocytosisPLoS Medicine, 2007
- Neuropathology of CNS disease in Langerhans cell histiocytosisBrain, 2005
- Retinoic acid therapy in “degenerative‐like” neuro‐langerhans cell histiocytosis: A prospective pilot studyPediatric Blood & Cancer, 2004
- Langerhans Cell Histiocytosis of Hypothalamus and Optic ChiasmJournal of Computer Assisted Tomography, 1991
- Computed tomography demonstration of multiple parenchymal central nervous system nodules due to histiocytosis xSurgical Neurology, 1987
- ISOLATED ABDUCENS NUCLEUS DAMAGE DUE TO HISTIOCYTOSIS XBrain, 1984